EANM procedure guidelines for therapy of benign thyroid disease
- PMID: 20625722
- DOI: 10.1007/s00259-010-1536-8
EANM procedure guidelines for therapy of benign thyroid disease
Abstract
The purpose of the present guidelines on the (131)I therapy of benign thyroid disorders formulated by the European Association of Nuclear Medicine (EANM) Therapy Committee is to provide advice to nuclear medicine clinicians on how to treat benign thyroid conditions employing optimal (131)I activities. The recommendations were formulated based on recent literature and expert opinion regarding rationale, indications and contraindications for the use of (131)I procedures, as well as the adequate (131)I activities in different thyroid disorders, and the administration and patient preparation techniques to be used. Recommendations are also provided on history and examinations before (131)I therapy, patient counselling and precautions associated with (131)I therapy. Furthermore, potential side effects and alternative treatment modalities are reviewed. Special attention is paid to these aspects in the treatment of children undergoing this procedure.
Similar articles
-
Guidelines for radioiodine therapy of differentiated thyroid cancer.Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1941-59. doi: 10.1007/s00259-008-0883-1. Eur J Nucl Med Mol Imaging. 2008. PMID: 18670773
-
EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases.Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1126-34. doi: 10.1007/s00259-013-2387-x. Epub 2013 Apr 11. Eur J Nucl Med Mol Imaging. 2013. PMID: 23576099
-
The EANM guideline on radioiodine therapy of benign thyroid disease.Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3324-3348. doi: 10.1007/s00259-023-06274-5. Epub 2023 Jul 3. Eur J Nucl Med Mol Imaging. 2023. PMID: 37395802 Free PMC article.
-
Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):821-8. doi: 10.1007/s00259-010-1398-0. Eur J Nucl Med Mol Imaging. 2010. PMID: 20186542 Review. No abstract available.
-
Benign thyroid disease: what is the role of nuclear medicine?Semin Nucl Med. 2006 Jul;36(3):185-93. doi: 10.1053/j.semnuclmed.2006.03.006. Semin Nucl Med. 2006. PMID: 16762609 Review.
Cited by
-
Iodine-131 induced hepatotoxicity in previously healthy patients with Grave's disease.Thyroid Res. 2013 Mar 16;6:4. doi: 10.1186/1756-6614-6-4. eCollection 2013. Thyroid Res. 2013. PMID: 23497434 Free PMC article.
-
Comparison of Otsu and an adapted Chan-Vese method to determine thyroid active volume using Monte Carlo generated SPECT images.EJNMMI Phys. 2024 Jan 8;11(1):6. doi: 10.1186/s40658-023-00609-9. EJNMMI Phys. 2024. PMID: 38189877 Free PMC article.
-
Lithium carbonate as add-on therapy to radioiodine in the treatment on hyperthyroidism: a systematic review and meta-analysis.BMC Endocr Disord. 2021 Apr 12;21(1):64. doi: 10.1186/s12902-021-00729-2. BMC Endocr Disord. 2021. PMID: 33840391 Free PMC article.
-
3D printed non-uniform anthropomorphic phantoms for quantitative SPECT.EJNMMI Phys. 2024 Jan 22;11(1):8. doi: 10.1186/s40658-024-00613-7. EJNMMI Phys. 2024. PMID: 38252205 Free PMC article.
-
The assessment of radio-adaptive response in graves' hyperthyroidism patients following radioactive iodine uptake.World J Nucl Med. 2018 Oct-Dec;17(4):270-274. doi: 10.4103/wjnm.WJNM_83_17. World J Nucl Med. 2018. PMID: 30505225 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical